Contact us

Thank you for your interest in Garg Law PLLC.

Our commitment to understanding your regulatory questions and business goals, and helping you achieve results starts here.

If you are looking for representation on a new matter, please fill out the form below to request a free consultation. The form enables us to conduct a preliminary check for potential conflicts of interest and to determine if we can proceed with the free consultation.

Medical Device Regulatory Attorney in Brickell

If your Brickell business has an FDA question that cannot wait — a medical device regulatory matter, an inspection, a deadline — start with what the rules actually require. Brickell is the financial capital of Latin American trade — the banks that finance Miami’s imports, the regional headquarters that direct them, and the executives who make product and market-entry decisions for the hemisphere all sit within a few blocks. Garg Law’s Miami office is here, at 1221 Brickell Avenue, in the middle of that corridor. The companies steering FDA-regulated product lines from Brickell towers need regulatory answers at deal speed — and the office handling them is on the same street.

The short answer

Device regulation runs from classification through clearance, registration, listing, quality systems and post-market reporting — and importers inherit their own slice of it as initial importers. The strategy work is choosing the right pathway; the survival work is keeping registrations, listings and quality records aligned when FDA looks.

What a medical device regulatory matter really involves

Every device question starts with classification: Class I, II or III determines whether the product needs a 510(k) clearance, a De Novo, a PMA — or only general controls. Getting there is a claims-and-technology analysis against FDA’s classification regulations, and it decides your cost, timeline and evidence burden before anything else does.

Operational compliance follows: annual establishment registration (with user fees) and device listing for manufacturers, specification developers and initial importers; foreign establishments need a U.S. agent. The quality system regulation governs design and production controls; UDI labeling, medical device reporting (MDR) for adverse events, and corrections-and-removals reporting round out the post-market regime.

Miami is one of the country’s busiest medical device trade corridors — manufacturing and distribution across the region, exports throughout Latin America, and imports through MIA daily. Import screening tests registrations and listings on every entry; unlisted devices, missing premarket clearance and labeling gaps surface as holds and detentions at exactly the wrong time.

How Garg Law handles it

  1. Classification and pathway strategy: 510(k), De Novo, PMA or exempt — with predicate and claims analysis
  2. Registration and listing architecture across manufacturers, importers and specification developers
  3. Quality system and labeling compliance, including UDI and the design controls FDA inspects
  4. Import compliance: initial-importer obligations, entry affirmations, and detention response for flagged shipments
  5. Post-market management — MDR reporting, corrections and removals, recall strategy and inspection response

Why Brickell manufacturers call us

The work around Brickell — international banking and trade finance, multinational regional headquarters, consumer brand offices, legal and professional services, import/export holding companies — is FDA-regulated at nearly every turn, and matters here move on Miami’s financial district, home to the banks, trade finance desks and regional headquarters that fund and direct hemispheric trade. Garg Law's Miami office is at 1221 Brickell Avenue, and the practice was built for exactly this market: founder Shelly Garg spent years counseling importers at the world's largest dedicated international trade law firm before opening her own, and works at the crossroads of FDA and CBP compliance for foreign and domestic companies across the food, beverage, supplement, cosmetics, OTC drug and medical device industries.

What not to do

  • Marketing claims that outrun the 510(k) — new intended uses need new clearance
  • Assuming the foreign manufacturer’s registration covers the U.S. importer — initial importers register too
  • Skipping listing updates when products, models or labeling change
  • Treating quality-system documentation as paperwork until the Form 483 arrives
  • Importing devices without verifying clearance status and listing before the goods ship

Frequently asked questions

Does my product even count as a medical device?

If it is intended to diagnose, treat, mitigate or prevent disease, or affects body structure or function without chemical action, it likely does — and intended use is read from your claims. Wellness gadgets become regulated devices through marketing language all the time; the analysis is worth doing before launch.

What is the difference between 510(k), De Novo and PMA?

A 510(k) shows substantial equivalence to an existing predicate device; De Novo creates a new classification for novel lower-risk devices; PMA is full premarket approval with clinical evidence for Class III. Pathway choice is the single biggest driver of time and cost to market.

What does an initial importer of devices have to do?

Register as an establishment, ensure the devices are listed and properly cleared or approved, and maintain complaint-handling and MDR obligations. Importers who assume the foreign manufacturer handles FDA discover otherwise at the border — or during an inspection.

Why was my device shipment held at MIA?

Typical bases: the entry could not verify registration and listing, the device appeared to lack required clearance, labeling issues, or the manufacturer has inspection history. Entry affirmations must match FDA’s records exactly — mismatches read as violations even when the paperwork exists.

When must a device problem be reported to FDA?

Under MDR, deaths, serious injuries and malfunctions that could cause them must be reported on statutory timelines — generally within 30 days, faster for some events. Corrections and removals in the field carry their own reporting rule. Late awareness is not a defense; complaint systems exist to catch these in time.

Related help nearby

Request a Consultation

★★★★★

Working with Shelly on various new product launches over the last couple of years has been seamless. Quick and clear guidance is always what we get.
R.G. Client
I've been working with Shelly and her team at Garg law for a little while now and they are fantastic! Very responsive, professional and they certainly get things done. Extremely satisfied with their service and highly recommend.
Mike H. Client
Ms Garg helped my company navigate an FDA import issue. She achieved an excellent result, was very responsive and professional, and managed to keep the project within budget. She is a stellar attorney.
Dr. Sastry Client
I have been using Shelly Garg as FDA Counsel for 10+ years, since she was at another international law firm. While we continued to use the previous firm she was at (mainly due to the process required to change firms), we realized the quality of counsel was not the same. We have since been using Garg Law and the ease of use and trust in the knowledge was back instantly. Shelly has the skills to help me understand the regulations (by translating into layman's terms) and risks in a manner that is specific to my business. She is also extremely timely in her responses which is critical when we have a deadline mandated by the FDA. Many other attorneys cite the regulations which l've already read, but need further counsel. In my opinion, this demonstrates Shelly's in-depth knowledge of the regulations, how they pertain to the law, and how they are applicable IRL. Shelly's personable approach and pleasant manner in communication makes it very easy to have been work with her and have productive discussions on the best next steps. She truly has a passion iternational for all things FDA and I've learned so much from her.
Claire P. Client

News & Insights

Get the latest news on FDA regulatory delivered straight to your inbox.